Complement-inactivating Proteinase(s) from Clostridium histolyticum

i83. THE PROTEINASES OF CLOSTRIDIUM HISTOLYTICUM

Toxigenicity of Clostridium histolyticum.

Nishida, Shoki (Kanazawa University, Kanazawa, Japan), and Masaaki Imaizumi. Toxigenicity of Clostridium histolyticum. J. Bacteriol. 91:477-483. 1966.-From 234 soil samples, 21 strains of Clostridium histolyticum of different levels of alpha-toxigenicity were isolated by a new method specially designed for the isolation of this species. The alpha-toxigenicity of freshly isolated strains and of ...

Enzymatic debridement of third-degree burns on guinea pigs by Clostridium histolyticum proteinases.

Webster, Marion E. (Walter Reed Army Institute of Research, Washington, D. C.), Patricia L. Altieri, David A. Conklin, Sanford Berman, Joseph P. Lowenthal, and Raymond B. Gochenour. Enzymatic debridement of third-degree burns on guinea pigs by Clostridium histolyticum proteinases. J. Bacteriol. 83:602-608. 1962.-An attempt has been made to correlate in vitro activities of Clostridium histolytic...

[Treatment of Dupuytren's disease using collagenase from Clostridium histolyticum].

OBJECTIVE The collagenase from Clostridium histolyticum is a new therapeutic option, and the first pharmacological one, in the treatment of Dupuytren's disease. MATERIAL AND METHODS A prospective study was conducted on 35 patients with Dupuytren's disease. The clinical and functional variables, as well as patient satisfaction and drug safety were evaluated. RESULTS The functional and clinic...

Injectable collagenase clostridium histolyticum for Dupuytren's contracture.

BACKGROUND Dupuytren's disease limits hand function, diminishes the quality of life, and may ultimately disable the hand. Surgery followed by hand therapy is standard treatment, but it is associated with serious potential complications. Injection of collagenase clostridium histolyticum, an office-based, nonsurgical option, may reduce joint contractures caused by Dupuytren's disease. METHODS W...